Remedy Plan

Washington, United States Founded: 2011 • Age: 15 yrs
Metastatic cancer properties are targeted by Remedy Plans containment therapy.

About Remedy Plan

Remedy Plan is a Healthcare company based in Washington (United States) founded in 2011. Metastatic cancer properties are targeted by Remedy Plans containment therapy. It operates on a HealthTech model. Remedy Plan has raised $24.7 million across 3 funding rounds from investors including ARE and Schooner Capital. Remedy Plan offers products and services including RPT1G, NAMPT Autoimmune Drug, and NAMPT Obesity Drug. Its focus areas include Biotechnology, Oncology, Autoimmune Disorders and Metabolic Disorders. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.

Company details

Remedy Plan is engaged in the development of innovative therapeutics targeting NAMPT, a key regulator of cellular energy metabolism. The companys efforts are directed towards addressing diseases in oncology, autoimmune disorders, and metabolic conditions. A proprietary drug screening platform is utilized to discover and optimize drugs, with their lead candidate RPT1G advancing in clinical trials for oncology. Solutions are being explored to overcome historical toxicity challenges in NAMPT inhibition, offering potential treatments across multiple health sectors.

Operational Areas
Key Metrics
  • Total Equity Funding
    $24.7M (USD)

    in 3 rounds

  • Latest Funding Round
    $18M (USD), Series B

    May 2025

  • Investors
    ARE

    & 1 more

Products & Services of Remedy Plan

Remedy Plan offers a comprehensive portfolio of products and services, including RPT1G, NAMPT Autoimmune Drug, and NAMPT Obesity Drug.

RPT1G
Oncology Drug

A novel NAMPT inhibitor for oncology treatment is developed.

NAMPT Autoimmune Drug
Autoimmune Drug

A NAMPT inhibitor for autoimmune diseases is being researched.

NAMPT Obesity Drug
Metabolic Drug

A NAMPT inhibitor for obesity treatment is under development.

Funding Insights of Remedy Plan

Remedy Plan has successfully raised a total of $24.7M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $18 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $24.7M
  • Total Rounds 3
  • Last Round Series B β€” $18M
  • First Round $1.5M

    (Nov 2018)

  • Investors Count 2

All 3 funding rounds of Remedy Plan with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2025$18MSeries B––
Dec 2019$5.2MSeries A––
–
Nov 2018$1.5MSeries A––
–
Valuation history

2 investors in total: 2 institutional.

Investors in Remedy Plan

Remedy Plan has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE and Schooner Capital.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Private equity investments are directed across multiple sectors.
schoonercapital.comBoston, United States
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US
1994are.comPasadena, United States
Premium access

Investor details for Remedy Plan

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Remedy Plan

18 people are tracked at Remedy Plan (5 in leadership, 8 in board & advisors, 5 in team).

NameRoleGroup
Greg Crimmins
CEO & FounderLeadership
Dennise A. De Jesús-Díaz
Chief Operations OfficerLeadership
Michael Schelle
Chief Scientific OfficerLeadership
Marc Rudoltz
Acting Chief Medical OfficerLeadership
Banumathi Cole
Director, BiologyLeadership
Frank McCormick
AdvisorBoard & advisors
Ronald Parchem
AdvisorBoard & advisors
Vahe Bedian
AdvisorBoard & advisors
Daniel Portnoy
AdvisorBoard & advisors
Tom Dubensky
AdvisorBoard & advisors
Erika Pearce
AdvisorBoard & advisors
Ed Pearce
AdvisorBoard & advisors
Steve Abella
AdvisorBoard & advisors
Parisa Moghaddam-Taaheri
Program ManagerTeam
Claudia Fabiola Ramos
Research AssistantTeam
James Digel
Research Technician ITeam
Min Wu
Senior Scientist, BiologyTeam
Caroline Robb
Senior Project ManagerTeam
Premium access

Complete people profiles for Remedy Plan

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Remedy Plan

3 dated milestones of Remedy Plan across 14 years, from founding to its latest funding, stage changes and deals.

  1. Founded Remedy Plan is founded.
  2. Funding First funding round of $1.5M.
  3. Funding Latest funding round, Series B, of $18.0M.

Competitors of Remedy Plan

Remedy Plan has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
modernatx.com2010Cambridge, United States$2.78B1,312
mRNA-based therapeutics for diseases including cancer and infections are developed.
beigene.com2010Cambridge, United States$172M1,090
Targeted and immune-oncology drugs for cancer treatment are developed.
incyte.com1991Wilmington, United States1,387
Small molecules are developed for cancer and skin disease treatments.
Premium access

Detailed competitors of Remedy Plan

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Remedy Plan

The website of Remedy Plan (remedyplan.com) receives about 2.2K visits a month.

  • Monthly visits
    2.2K

    ▲ 28.4% vs previous month

Top companies in Oncology

3 companies that operate in the same segment as Remedy Plan (Oncology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Remedy Plan

Premium access

Complete news archive for Remedy Plan

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Remedy Plan

Remedy Plan was founded in 2011 and raised its 1st funding round 7 years after it was founded.

Remedy Plan is headquartered in Washington, United States. It is registered at Washington, District Of Columbia, United States.

Remedy Plan is a funded company, having raised a total of $24.7M across 3 funding rounds to date. The company's 1st funding round was a Series A of $1.5M, raised on Nov 2018.

Remedy Plan is engaged in the development of innovative therapeutics targeting NAMPT, a key regulator of cellular energy metabolism. The companys efforts are directed towards addressing diseases in oncology, autoimmune disorders, and metabolic conditions. A proprietary drug screening platform is utilized to discover and optimize drugs, with their lead candidate RPT1G advancing in clinical trials for oncology. Solutions are being explored to overcome historical toxicity challenges in NAMPT inhibition, offering potential treatments across multiple health sectors.

Remedy Plan's top competitors include Moderna, BeiGene and Incyte.

Remedy Plan offers RPT1G, NAMPT Autoimmune Drug, and NAMPT Obesity Drug.

Remedy Plan has 2 investors. Key investors include ARE, and Schooner Capital.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available